• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一位阵发性共济失调、肌束震颤、痛性痉挛和代谢功能障碍患者的 KCNA1 基因突变。

A novel KCNA1 mutation in a patient with paroxysmal ataxia, myokymia, painful contractures and metabolic dysfunctions.

机构信息

Department of Pharmacy - Drug Sciences, University of Bari Aldo Moro, Bari, Italy.

Department of Pharmacy - Drug Sciences, University of Bari Aldo Moro, Bari, Italy.

出版信息

Mol Cell Neurosci. 2017 Sep;83:6-12. doi: 10.1016/j.mcn.2017.06.006. Epub 2017 Jun 28.

DOI:10.1016/j.mcn.2017.06.006
PMID:28666963
Abstract

Episodic ataxia type 1 (EA1) is a human dominant neurological syndrome characterized by continuous myokymia, episodic attacks of ataxic gait and spastic contractions of skeletal muscles that can be triggered by emotional stress and fatigue. This rare disease is caused by missense mutations in the KCNA1 gene coding for the neuronal voltage gated potassium channel Kv1.1, which contributes to nerve cell excitability in the cerebellum, hippocampus, cortex and peripheral nervous system. We identified a novel KCNA1 mutation, E283K, in an Italian proband presenting with paroxysmal ataxia and myokymia aggravated by painful contractures and metabolic dysfunctions. The E283K mutation is located in the S3-S4 extracellular linker belonging to the voltage sensor domain of Kv channels. In order to test whether the E283K mutation affects Kv1.1 biophysical properties we transfected HEK293 cells with WT or mutant cDNAs alone or in a 1:1 combination, and recorded relative potassium currents in the whole-cell configuration of patch-clamp. Mutant E283K channels display voltage-dependent activation shifted by 10mV toward positive potentials and kinetics of activation slowed by ~2 fold compared to WT channels. Potassium currents resulting from heteromeric WT/E283K channels show voltage-dependent gating and kinetics of activation intermediate between WT and mutant homomeric channels. Based on homology modeling studies of the mutant E283K, we propose a molecular explanation for the reduced voltage sensitivity and slow channel opening. Overall, our results suggest that the replacement of a negatively charged residue with a positively charged lysine at position 283 in Kv1.1 causes a drop of potassium current that likely accounts for EA-1 symptoms in the heterozygous carrier.

摘要

发作性共济失调 1 型(EA1)是一种人类显性神经系统综合征,其特征为持续肌束颤动、发作性共济失调步态和骨骼肌痉挛性收缩,这些症状可由情绪压力和疲劳引发。这种罕见疾病是由编码神经元电压门控钾通道 Kv1.1 的 KCNA1 基因突变引起的,该基因突变导致小脑、海马体、大脑皮层和周围神经系统的神经细胞兴奋性增加。我们在一位意大利先证者中发现了一种新的 KCNA1 突变 E283K,该先证者表现为发作性共济失调和肌束颤动,伴有疼痛性挛缩和代谢功能障碍加重。E283K 突变位于 Kv 通道电压传感器域的 S3-S4 细胞外环连接区。为了测试 E283K 突变是否影响 Kv1.1 的生物物理特性,我们单独转染 WT 或突变 cDNA 或 1:1 组合的 WT 和突变 cDNA 到 HEK293 细胞中,并在膜片钳全细胞模式下记录相对钾电流。与 WT 通道相比,突变 E283K 通道的电压依赖性激活向正电位偏移 10mV,激活动力学减慢约 2 倍。来自异源 WT/E283K 通道的钾电流表现出电压依赖性门控和激活动力学介于 WT 和突变同型通道之间。基于突变体 E283K 的同源建模研究,我们提出了一种分子解释,说明负电荷残基被正电荷赖氨酸取代导致钾电流下降,这可能是杂合子携带者中 EA1 症状的原因。

总体而言,我们的研究结果表明,在 Kv1.1 中,第 283 位带负电荷的氨基酸被带正电荷的赖氨酸取代,导致钾电流下降,这可能导致了 EA1 患者的症状。

相似文献

1
A novel KCNA1 mutation in a patient with paroxysmal ataxia, myokymia, painful contractures and metabolic dysfunctions.一位阵发性共济失调、肌束震颤、痛性痉挛和代谢功能障碍患者的 KCNA1 基因突变。
Mol Cell Neurosci. 2017 Sep;83:6-12. doi: 10.1016/j.mcn.2017.06.006. Epub 2017 Jun 28.
2
The episodic ataxia type 1 mutation I262T alters voltage-dependent gating and disrupts protein biosynthesis of human Kv1.1 potassium channels.发作性共济失调1型突变I262T改变电压依赖性门控并破坏人Kv1.1钾通道的蛋白质生物合成。
Sci Rep. 2016 Jan 18;6:19378. doi: 10.1038/srep19378.
3
Two novel KCNA1 variants identified in two unrelated Chinese families affected by episodic ataxia type 1 and neurodevelopmental disorders.在两个无关联的中国家庭中发现的两个新型 KCNA1 变体,受发作性共济失调 1 型和神经发育障碍的影响。
Mol Genet Genomic Med. 2020 Oct;8(10):e1434. doi: 10.1002/mgg3.1434. Epub 2020 Jul 23.
4
A Common Kinetic Property of Mutations Linked to Episodic Ataxia Type 1 Studied in the Shaker Kv Channel.与发作性共济失调症 1 型相关突变的共同动力学特性在 Shaker Kv 通道中的研究。
Int J Mol Sci. 2020 Oct 14;21(20):7602. doi: 10.3390/ijms21207602.
5
Episodic ataxia type 1 mutations in the KCNA1 gene impair the fast inactivation properties of the human potassium channels Kv1.4-1.1/Kvbeta1.1 and Kv1.4-1.1/Kvbeta1.2.KCNA1基因中的发作性共济失调1型突变损害了人类钾通道Kv1.4 - 1.1/Kvbeta1.1和Kv1.4 - 1.1/Kvbeta1.2的快速失活特性。
Eur J Neurosci. 2006 Dec;24(11):3073-83. doi: 10.1111/j.1460-9568.2006.05186.x.
6
A novel KCNA1 mutation identified in an Italian family affected by episodic ataxia type 1.在一个受发作性共济失调1型影响的意大利家族中鉴定出一种新的KCNA1突变。
Neuroscience. 2008 Dec 2;157(3):577-87. doi: 10.1016/j.neuroscience.2008.09.022. Epub 2008 Sep 24.
7
Kcna1-mutant rats dominantly display myokymia, neuromyotonia and spontaneous epileptic seizures.Kcna1 突变型大鼠主要表现为肌纤维震颤、神经肌强直和自发性癫痫发作。
Brain Res. 2012 Jan 30;1435:154-66. doi: 10.1016/j.brainres.2011.11.023. Epub 2011 Nov 13.
8
Dominant-negative mutation p.Arg324Thr in KCNA1 impairs Kv1.1 channel function in episodic ataxia.KCNA1基因中的显性负性突变p.Arg324Thr损害发作性共济失调中的Kv1.1通道功能。
Mov Disord. 2016 Nov;31(11):1743-1748. doi: 10.1002/mds.26737. Epub 2016 Aug 1.
9
A channelopathy mutation in the voltage-sensor discloses contributions of a conserved phenylalanine to gating properties of Kv1.1 channels and ataxia.电压传感器中的通道病突变揭示了保守苯丙氨酸对 Kv1.1 通道和共济失调门控特性的贡献。
Sci Rep. 2017 Jul 4;7(1):4583. doi: 10.1038/s41598-017-03041-z.
10
Episodic ataxia type 1 mutations affect fast inactivation of K+ channels by a reduction in either subunit surface expression or affinity for inactivation domain.发作性共济失调 1 型突变通过降低亚基表面表达或失活域亲和力来影响 K+通道的快速失活。
Am J Physiol Cell Physiol. 2011 Jun;300(6):C1314-22. doi: 10.1152/ajpcell.00456.2010. Epub 2011 Feb 9.

引用本文的文献

1
A conifer metabolite corrects episodic ataxia type 1 by voltage sensor-mediated ligand activation of Kv1.1.一种针叶树代谢产物通过电压传感器介导的Kv1.1配体激活来纠正1型发作性共济失调。
Proc Natl Acad Sci U S A. 2025 Jan 14;122(2):e2411816122. doi: 10.1073/pnas.2411816122. Epub 2024 Dec 30.
2
Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets.《结节性硬化症的治疗方法:从现有疗法到有前途的药物靶点》。
Biomolecules. 2024 Sep 21;14(9):1190. doi: 10.3390/biom14091190.
3
Potassium channel-related epilepsy: Pathogenesis and clinical features.
钾离子通道相关性癫痫:发病机制与临床特征。
Epilepsia Open. 2024 Jun;9(3):891-905. doi: 10.1002/epi4.12934. Epub 2024 Apr 1.
4
Novel Genetic Variants Expand the Functional, Molecular, and Pathological Diversity of Channelopathy.新型遗传变异扩大了通道病的功能、分子和病理多样性。
Int J Mol Sci. 2023 May 16;24(10):8826. doi: 10.3390/ijms24108826.
5
Episodic Ataxias: Primary and Secondary Etiologies, Treatment, and Classification Approaches.发作性共济失调:主要和次要病因、治疗和分类方法。
Tremor Other Hyperkinet Mov (N Y). 2023 Mar 28;13:9. doi: 10.5334/tohm.747. eCollection 2023.
6
Rubbing Salt in the Wound: Molecular Evolutionary Analysis of Pain-Related Genes Reveals the Pain Adaptation of Cetaceans in Seawater.往伤口上撒盐:疼痛相关基因的分子进化分析揭示了鲸类在海水中的疼痛适应性
Animals (Basel). 2022 Dec 16;12(24):3571. doi: 10.3390/ani12243571.
7
Clinical and Functional Study of a De Novo Variant in the PVP Motif of Kv1.1 Channel Associated with Epilepsy, Developmental Delay and Ataxia.Kv1.1 通道 PVP 基序中新发变异与癫痫、发育迟缓伴共济失调的临床和功能研究。
Int J Mol Sci. 2022 Jul 22;23(15):8079. doi: 10.3390/ijms23158079.
8
Distinct epilepsy phenotypes and response to drugs in KCNA1 gain- and loss-of function variants.KCNA1 功能获得和功能丧失变异体中不同的癫痫表型和对药物的反应。
Epilepsia. 2022 Jan;63(1):e7-e14. doi: 10.1111/epi.17118. Epub 2021 Nov 14.
9
A Novel Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine.一个患有非进行性先天性共济失调和癫痫的患者中的新型变异:功能特征和对 4-氨基吡啶的敏感性。
Int J Mol Sci. 2021 Sep 14;22(18):9913. doi: 10.3390/ijms22189913.
10
Musculoskeletal Features without Ataxia Associated with a Novel de novo Mutation in Impairing the Voltage Sensitivity of Kv1.1 Channel.与Kv1.1通道电压敏感性受损的新型从头突变相关的无共济失调的肌肉骨骼特征
Biomedicines. 2021 Jan 14;9(1):75. doi: 10.3390/biomedicines9010075.